Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|6|483-486

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.6, 2015-06, pp. : 483-486

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 118, Iss. 1, 2007-03 ,pp. : 7-9

Karger

Access to resources Recommend Favorite

G‐CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 295-300

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I/II study of oral clofarabine plus low‐dose cytarabine in previously treated acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients at least 60 years of age

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 3, 2015-08 ,pp. : 349-355

John Wiley & Sons Inc

Access to resources Recommend Favorite

Angiogenesis in Acute Myeloid Leukemia and Myelodysplastic Syndrome

By  

Acta Haematologica, Vol. 106, Iss. 4, 2002-01 ,pp. : 170-176

Karger

Access to resources Recommend Favorite

Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 137, Iss. 4, 2017-04 ,pp. : 195-200

Karger

Access to resources Recommend Favorite